Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Deambulazione assistita per migliorare i risultati sanitari per i pazienti ricoverati medici più anziani

4 novembre 2026 aggiornato da: Michael Rothberg, The Cleveland Clinic

Prova randomizzata di deambulazione assistita per migliorare i risultati sanitari per i pazienti ricoverati medici più anziani

The investigator proposes to conduct a randomized trial of supervised ambulation delivered by mobility technician (MT) up to three times daily, including weekends, to hospitalized medical patients. The aims of the study are to compare the short and intermediate-term outcomes of patients randomized to the intervention versus those patients randomized to receive usual care, to identify patients who are most likely to benefit from the intervention and to assess whether the intervention increases or decreases overall costs of an episode of care, including the cost of the MTs, the index hospitalization and the first 30 days post enrollment.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The investigator proposes to conduct a large randomized trial to test the impact of MTs (Mobility Technicians) on short and intermediate term outcomes for 3000 patients aged 65 years and older at 5 hospitals in 2 health systems. Patients will be randomized to receive supervised ambulation up to 3 times daily with a MT or to receive usual care. All participants will wear an accelerometer on their wrist to track their movement throughout the hospital stay. The study has 3 aims. First, the study will compare the mobility of patients at discharge (or 10 days) to assess the impact of the MTs on this outcome. Of particular interest is whether the use of MTs will increase the proportion of patients who can go home vs.post-acute care, and whether the improvements in mobility are sustained at 30 days. Second, the study will use predictive modeling to identify which patients are most likely to benefit from this intervention. Third, the study will assess the impact of the intervention on overall costs associated with the episode of care, including inpatient costs and the 30 days post enrollment. This information will be important to convince health systems to adopt this approach.

Tipo di studio

Interventistico

Iscrizione (Stimato)

3000

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Michael Rothberg, M.D.
  • Numero di telefono: 216-445-0719
  • Email: rothbem@ccf.org

Luoghi di studio

    • Massachusetts
      • Springfield, Massachusetts, Stati Uniti, 01199
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44111
        • Reclutamento
        • Fairview Hospital
        • Contatto:
          • Michael Rothberg, MD
          • Numero di telefono: 216-445-0719
          • Email: rothbem@ccf.org
      • Cleveland, Ohio, Stati Uniti, 44195
        • Reclutamento
        • Cleveland Clinic- Main Campus
        • Contatto:
          • Michael Rothberg, MD
          • Numero di telefono: 216-445-0719
          • Email: rothbem@ccf.org
      • Garfield Heights, Ohio, Stati Uniti, 44125
        • Terminato
        • Marymount Hospital
      • Mayfield Heights, Ohio, Stati Uniti, 44124
        • Reclutamento
        • Hillcrest Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

65 anni e precedenti (Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Participants must meet all of the inclusion criteria listed below to participate in this study:

  1. ≥65 years of age
  2. Admitted to a medical service
  3. Complete history and physical examination on file
  4. 6-Clicks score of 16-23
  5. Insurance with Traditional Medicare or Medicare Advantage

Exclusion Criteria:

Any patient meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:

  1. Significant language barrier that requires a translator (other than Spanish at Baystate site only)
  2. Discharge planned for that day or the following day
  3. Observation status
  4. Surgical procedure planned
  5. Patients diagnosed with unstable angina or other medical conditions precluding participation in exercise/ambulation
  6. Permanent residence in a skilled nursing facility
  7. Comfort care measures only
  8. >48 hours since admission
  9. Active infection with COVID-19
  10. Other active infection requiring contact or droplet precautions
  11. Order for bedrest

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Usual Care

No intervention

Sperimentale: Mobility Technician

Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session

Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Short Physical Performance Battery (SPPB) from admission
Lasso di tempo: Up to 10 days

Every patient will have an SPPB score on admission to the study. A blinded assessor will measure the SPPB again at discharge or on day 10 if the patient is still hospitalized. The primary outcome is change from admission to discharge. Investigators will also compare the percentage of patients who reach the minimal clinically important difference of 1 point.

SPPB minimum value= 0 SPPB maximum value= 12 (higher score indicates a better outcome). If no blinded team member is available, the evaluation may be carried out by any unblinded team member. The blinding status of the evaluator will be noted in REDCap.

Up to 10 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient-Reported Outcomes Measurement Information System (PROMIS) physical function - mobility
Lasso di tempo: 30 days post enrollment

Patients will complete the PROMIS physical function mobility bank via REDCap at 30 days post enrollment. PROMIS allows use of computer-adapted testing to measure patient-reported outcomes. The mobility question bank focuses on activities of physical mobility such as getting out of bed or a chair to walking up stairs. PROMIS measures were developed and validated with state-of-the-science methods supported by National Institutes of Health (NIH) funding. PROMIS was designed to enhance communication between clinicians and patients in diverse research and clinical settings and to be relevant across all conditions for the assessment of symptoms and functions.

PROMIS minimum value= 0 PROMISE maximum value= 100 (higher score indicates a better outcome)

30 days post enrollment
Activity Measure for Post-Acute Care (AM-PAC) basic mobility outpatient short form (SF)
Lasso di tempo: 30 days post enrollment

Subjects will complete the AM-PAC at 30 days post enrollment and the score will be transformed using the t-scale. In addition to comparing AM-PAC scores at 30 days, the investigator will also compare change in t-score from admission. The AM-PAC 6-clicks (assessed in the hospital) and the AM-PAC outpatient SF are normed to the same t-scale, allowing for conversion from the one to the other. The 6-clicks is scored by a clinical proxy, while the SF AM-PAC is self-reported, allowing for initial assessment by the MT and 30-day self-report by the patient. Previous studies have demonstrated adequate validity of mobility assessment via the AM-PAC using clinical or family proxies. To improve interpretability, investigators will compare the percentage of patients who reach the minimal clinically important difference of 3 points on the t-scale.

AM-PAC minimum value= 29.41 AM-PAC maximum value= 80.30 (higher score indicates a better outcome)

30 days post enrollment
Hospital-Acquired Complications
Lasso di tempo: 10 days

Composite outcome of venous thromboembolism, fall with injury, pressure ulcers or hospital-acquired pneumonia. Hospital-acquired complications will be identified from the electronic health record and from the falls reporting system. All falls will be examined, whether occurring during assisted ambulation or otherwise. Only falls with injury will be included in the hospital-acquired complications measure. Outcomes will be adjudicated by blinded reviewers. While investigators are primarily interested in the composite measure, investigators will also examine the individual components separately.

10 days
Number of Patients with Readmission within 30 days
Lasso di tempo: 30 days after discharge

All cause readmission within 30 days of discharge from the index hospitalization.

30 days after discharge
Activities of Daily Living
Lasso di tempo: 30 days post enrollment

Activities of daily living as measured by the Katz and Lawton scales.

Katz minimum value= 0 Katz maximum value= 6 (higher score indicates a better outcome) Lawton minimum value= 0 Lawton maximum value= 8 (higher score indicates a better outcome)

30 days post enrollment
Frailty
Lasso di tempo: 30 days post enrollment

Frailty as measured by the Fatigue, Resistance, Ambulation,Illness, and Loss of weight (FRAIL) scale.

FRAIL minimum value= 0 FRAIL maximum value= 5 (higher score indicates a worse outcome)

30 days post enrollment
Total episode cost
Lasso di tempo: Admission to 30 days post enrollment

Investigators will estimate total cost of the episode of care including the index admission (from hospital cost accounting systems), the personnel costs for the MTs (using hourly wages plus benefits), and all non-medication costs for the 30 days post-enrollment (from Medicare claims).

Admission to 30 days post enrollment
Number of Patients Discharged to Home
Lasso di tempo: date of randomization to date of discharge, up to 30 days

Based on the discharge disposition in the medical record, investigators will identify whether the patient was discharged to home.

date of randomization to date of discharge, up to 30 days
Length of Stay
Lasso di tempo: date of admission to date of discharge, up to 30 days

Length of stay will be calculated as whole days from the time of admission to the time of discharge.

date of admission to date of discharge, up to 30 days
Mortality
Lasso di tempo: 30 days from admission

Patient's vital status will be ascertained from the EHR, Medicare claims or from follow-up phone calls.

30 days from admission
Total episode cost
Lasso di tempo: Admission to 6 months after enrollment

Investigators will estimate total cost of the episode of care including the index admission (from hospital cost accounting systems), the personnel costs for the MTs (using hourly wages plus benefits), and all non-medication costs for the 6 months post-enrollment (from Medicare claims).

Admission to 6 months after enrollment
Falls post-discharge
Lasso di tempo: 30 days from admission

Whether the patient has fallen, whether it was multiple times and whether an injury occurred will be assessed via telephone

30 days from admission
RCSQ (Richards Campbell Sleep Questionnaire)
Lasso di tempo: Days 1-10

Five question sleep survey which measures overall quality of sleep. Patients in both study arms will complete the questionnaire each morning regarding the previous night's sleep.

Days 1-10

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Michael Rothberg, M.D., The Cleveland Clinic

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 maggio 2023

Completamento primario (Stimato)

30 novembre 2026

Completamento dello studio (Stimato)

30 dicembre 2026

Date di iscrizione allo studio

Primo inviato

11 gennaio 2023

Primo inviato che soddisfa i criteri di controllo qualità

10 febbraio 2023

Primo Inserito (Effettivo)

13 febbraio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 22-426
  • 1R01AG073278-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .